Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
· Financial Post
VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026 in San Diego, CA. Read More
Visit asg-reflektory.pl for more information.